A Phase III Study of GS101 Injection to Dupixent®

NCT07386743 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

572

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG: GS101 injection
DRUG: DUPIXENT®

Sponsor

Jiangsu Genscend Biopharmaceutical Co., Ltd